跳至內容

吡非尼酮

維基百科,自由的百科全書
吡非尼酮
臨床資料
商品名英語Drug nomenclatureEsbriet, Pirespa, Etuary
AHFS/Drugs.comMonograph
MedlinePlusa615008
核准狀況
懷孕分級
給藥途徑By mouth
ATC碼
法律規範狀態
法律規範
藥物動力學數據
血漿蛋白結合率50–58%[7]
藥物代謝Liver (70–80% CYP1A2-mediated; minor contributions from CYP2C9, CYP2C19, CYP2D6 and CYP2E1)[7]
生物半衰期2.4 hours[7]
排泄途徑Urine (80%)[7]
識別資訊
  • 5-Methyl-1-phenylpyridin-2-one
CAS號53179-13-8
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard英語CompTox Chemicals Dashboard (EPA)
ECHA InfoCard100.150.129 編輯維基數據鏈接
化學資訊
化學式C12H11NO
摩爾質量185.23 g·mol−1
3D模型(JSmol英語JSmol
水溶性10mg/mL at 60 °C
  • CC1=CN(C(=O)C=C1)C2=CC=CC=C2
  • InChI=1S/C12H11NO/c1-10-7-8-12(14)13(9-10)11-5-3-2-4-6-11/h2-9H,1H3
  • Key:ISWRGOKTTBVCFA-UHFFFAOYSA-N

吡非尼酮(英語:Pirfenidone,商品名有 Pirespa 等)是一種含氮有機化合物,分子式C
12
H
11
NO
,用於治療特發性肺纖維化,其作用機制是通過下調生長因子以及I型和II型前膠原的表達來減輕肺纖維化[8][6]

參考文獻

[編輯]
  1. ^ 1.0 1.1 Esbriet® (pirfenidone) Film coated tablets. Roche Products Pty Limited. medsinfo.com.au. [8 January 2023]. (原始內容存檔於8 January 2023). 
  2. ^ Esbriet® (pirfenidone) Capsules. Roche Products Pty Limited. medsinfo.com.au. [8 January 2023]. (原始內容存檔於8 January 2023). 
  3. ^ Prescription medicines: registration of new chemical entities in Australia, 2016. Therapeutic Goods Administration (TGA). 21 June 2022 [10 April 2023]. (原始內容存檔於10 April 2023). 
  4. ^ Esbriet Product information. Health Canada. 25 April 2012 [8 January 2023]. (原始內容存檔於8 January 2023). 
  5. ^ Esbriet- pirfenidone capsule Esbriet- pirfenidone tablet, coated. DailyMed. 14 December 2022 [8 January 2023]. (原始內容存檔於8 January 2023). 
  6. ^ 6.0 6.1 Esbriet EPAR. European Medicines Agency. 17 September 2018 [19 June 2020]. (原始內容存檔於24 November 2020). 
  7. ^ 7.0 7.1 7.2 7.3 Esbriet 267 mg hard capsules. electronic Medicines Compendium. Intermune UK & I Ltd. 3 January 2014 [6 March 2014]. (原始內容存檔於12 October 2013). 
  8. ^ InterMune: Pirfenidone. InterMune. [17 December 2015]. (原始內容存檔於21 October 2020).